Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Analyst Ratings
Strong Buy
14 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BMRN Stock 12 Month Forecast
Average Price Target
$87.50
▲(57.60% Upside)
| Highest Price Target$120.00 | Average Price Target$87.50 | Lowest Price Target$55.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
$73→$61
Hold
9.87%
Upside
Downgraded
11/06/25
Bernstein
$95→$88
Buy
58.50%
Upside
Assigned
10/31/25
Evercore ISI
$110
Buy
98.13%
Upside
Reiterated
10/28/25
Truist Financial
$90→$80
Buy
44.09%
Upside
Reiterated
10/28/25
Wells Fargo
$90→$70
Buy
26.08%
Upside
Reiterated
10/28/25
Jefferies
$113
Buy
103.53%
Upside
Reiterated
10/28/25
Morgan Stanley
$104→$98
Buy
76.51%
Upside
Reiterated
10/28/25
William Blair
―
Hold
―
Reiterated
10/28/25
William Blair Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)We summarize BioMarin’s financial results compared to our estimates and consensus in exhibit 1 of the full report and our model updates in exhibit 2. Lower bound of 2025 revenue guidance raised, but non-GAAP EPS guidance lowered: The company raised the lower bound of its 2025 revenue guidance from 3.125 billion to 3.150 billion (upper bound remains $3.2 billion) and reaffirmed Voxzogo guidance of $900 million-$935 million. On the call, management cited the $221 million pre-tax acquired in-process research and development (IPR&D) charge associated with the acquisition of Inozyme as the driver of its change in profitability guidance, with non-GAAP operating margin guidance cut from 33%-34% to 26%-27% and non-GAAP diluted EPS from $4.40-$4.55 to $3.50-$3.60.
Raymond James
$85
Buy
53.10%
Upside
Reiterated
10/28/25
Oppenheimer
$98
Buy
76.51%
Upside
Reiterated
10/28/25
Barclays
$86→$80
Buy
44.09%
Upside
Reiterated
10/28/25
H.C. Wainwright
$60→$55
Hold
-0.94%
Downside
Reiterated
10/28/25
Wedbush
$94
Buy
69.31%
Upside
Reiterated
10/28/25
Bank of America Securities
$103→$102
Buy
83.72%
Upside
Reiterated
10/27/25
J.P. Morgan
―
Buy
―
Reiterated
10/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
$73→$61
Hold
9.87%
Upside
Downgraded
11/06/25
Bernstein
$95→$88
Buy
58.50%
Upside
Assigned
10/31/25
Evercore ISI
$110
Buy
98.13%
Upside
Reiterated
10/28/25
Truist Financial
$90→$80
Buy
44.09%
Upside
Reiterated
10/28/25
Wells Fargo
$90→$70
Buy
26.08%
Upside
Reiterated
10/28/25
Jefferies
$113
Buy
103.53%
Upside
Reiterated
10/28/25
Morgan Stanley
$104→$98
Buy
76.51%
Upside
Reiterated
10/28/25
William Blair
―
Hold
―
Reiterated
10/28/25
William Blair Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)We summarize BioMarin’s financial results compared to our estimates and consensus in exhibit 1 of the full report and our model updates in exhibit 2. Lower bound of 2025 revenue guidance raised, but non-GAAP EPS guidance lowered: The company raised the lower bound of its 2025 revenue guidance from 3.125 billion to 3.150 billion (upper bound remains $3.2 billion) and reaffirmed Voxzogo guidance of $900 million-$935 million. On the call, management cited the $221 million pre-tax acquired in-process research and development (IPR&D) charge associated with the acquisition of Inozyme as the driver of its change in profitability guidance, with non-GAAP operating margin guidance cut from 33%-34% to 26%-27% and non-GAAP diluted EPS from $4.40-$4.55 to $3.50-$3.60.
Raymond James
$85
Buy
53.10%
Upside
Reiterated
10/28/25
Oppenheimer
$98
Buy
76.51%
Upside
Reiterated
10/28/25
Barclays
$86→$80
Buy
44.09%
Upside
Reiterated
10/28/25
H.C. Wainwright
$60→$55
Hold
-0.94%
Downside
Reiterated
10/28/25
Wedbush
$94
Buy
69.31%
Upside
Reiterated
10/28/25
Bank of America Securities
$103→$102
Buy
83.72%
Upside
Reiterated
10/27/25
J.P. Morgan
―
Buy
―
Reiterated
10/27/25
Best Analysts Covering BioMarin Pharmaceutical
1 Month
xxx
Success Rate
15/28 ratings generated profit
Average Return
-0.06%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.57% of your transactions generating a profit, with an average return of -0.06% per trade.
3 Months
xxx
Success Rate
14/36 ratings generated profit
Average Return
-0.74%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of -0.74% per trade.
1 Year
Success Rate
20/45 ratings generated profit
Average Return
-4.20%
reiterated a buy rating last month
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -4.20% per trade.
2 Years
xxx
Success Rate
15/45 ratings generated profit
Average Return
-4.56%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -4.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BMRN Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
24
26
27
34
19
Buy
16
18
19
18
8
Hold
7
5
7
10
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
47
49
53
62
35
Each month's total comprises the sum of three months' worth of ratings.
BMRN Financial Forecast
BMRN Stock Forecast FAQ
What is BMRN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 87.50.
What is BMRN’s upside potential, based on the analysts’ average price target?
BioMarin Pharmaceutical has 57.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BMRN a Buy, Sell or Hold?
BioMarin Pharmaceutical has a consensus rating of Strong Buy which is based on 14 buy ratings, 4 hold ratings and 0 sell ratings.
What is BioMarin Pharmaceutical’s price target?
The average price target for BioMarin Pharmaceutical is 87.50. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $55.00. The average price target represents 57.60% Increase from the current price of $55.52.
The highest analyst price target is $120.00 ,the lowest forecast is $55.00. The average price target represents 57.60% Increase from the current price of $55.52.
What do analysts say about BioMarin Pharmaceutical?
BioMarin Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of BMRN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.